{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T21:01:45Z","timestamp":1777323705221,"version":"3.51.4"},"reference-count":110,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["708370"],"award-info":[{"award-number":["708370"]}],"id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022706","name":"Cole Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022706","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Quebec Health Research Fund","doi-asserted-by":"publisher","award":["288558"],"award-info":[{"award-number":["288558"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019683","name":"Cole Foundation","doi-asserted-by":"publisher","award":["CIHR PJT-186077"],"award-info":[{"award-number":["CIHR PJT-186077"]}],"id":[{"id":"10.13039\/100019683","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020951","name":"Fonds de recherche du Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.omtn.2025.102611","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T11:43:01Z","timestamp":1750074181000},"page":"102611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["RNA activation of CEBPA improves leukemia treatment"],"prefix":"10.1016","volume":"36","author":[{"given":"Olivia","family":"Kovecses","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahram","family":"Sharif-Askari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristobal","family":"Gonzalez-Losada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikash","family":"Reebye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Br\u00edd M.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagy A.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan W.","family":"Luedtke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois E.","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3750-6027","authenticated-orcid":false,"given":"Maureen","family":"McKeague","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102611_bib1","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: a comprehensive review and 2016 update","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omtn.2025.102611_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000536152","article-title":"Pathophysiology of Acute Myeloid Leukemia","volume":"147","author":"Wachter","year":"2024","journal-title":"Acta Haematol."},{"key":"10.1016\/j.omtn.2025.102611_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41392-020-00422-1","article-title":"Interplay between cofactors and transcription factors in hematopoiesis and hematological malignancies","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2025.102611_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1151343","article-title":"Unveiling the complexity of transcription factor networks in hematopoietic stem cells: implications for cell therapy and hematological malignancies","volume":"13","author":"Benyoucef","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omtn.2025.102611_bib5","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1074\/jbc.270.10.4955","article-title":"Transcription Factors and Hematopoietic Development","volume":"270","author":"Orkin","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2025.102611_bib6","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/ng.3646","article-title":"Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution","volume":"48","author":"Corces","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102611_bib7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12185-015-1764-6","article-title":"C\/EBP\u03b1 in normal and malignant myelopoiesis","volume":"101","author":"Friedman","year":"2015","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.omtn.2025.102611_bib8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc989","article-title":"Disruption of differentiation in human cancer: AML shows the way","volume":"3","author":"Tenen","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omtn.2025.102611_bib9","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1038\/sj.onc.1210764","article-title":"Transcriptional control of granulocyte and monocyte development","volume":"26","author":"Friedman","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.omtn.2025.102611_bib10","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1101\/gad.10.7.804","article-title":"CCAAT\/enhancer-binding protein alpha (C\/EBP alpha) inhibits cell proliferation through the p21 (WAF-1\/CIP-1\/SDI-1) protein","volume":"10","author":"Timchenko","year":"1996","journal-title":"Genes Dev."},{"key":"10.1016\/j.omtn.2025.102611_bib11","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1097-2765(01)00366-5","article-title":"C\/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4","volume":"8","author":"Wang","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omtn.2025.102611_bib12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0092-8674(01)00516-5","article-title":"E2F repression by C\/EBPalpha is required for adipogenesis and granulopoiesis in vivo","volume":"107","author":"Porse","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102611_bib13","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1128\/MCB.20.16.5986-5997.2000","article-title":"C\/EBPalpha inhibits cell growth via direct repression of E2F-DP-mediated transcription","volume":"20","author":"Slomiany","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102611_bib14","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1128\/MCB.19.4.2936","article-title":"C\/EBPalpha regulates formation of S-phase-specific E2F-p107 complexes in livers of newborn mice","volume":"19","author":"Timchenko","year":"1999","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102611_bib15","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nrc904","article-title":"c-MYC: more than just a matter of life and death","volume":"2","author":"Pelengaris","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omtn.2025.102611_bib16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1079-9796(03)00135-9","article-title":"Regulation of granulocyte and monocyte differentiation by CCAAT\/enhancer binding protein \u03b1","volume":"31","author":"Friedman","year":"2003","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.omtn.2025.102611_bib17","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1182\/blood.V80.7.1725.1725","article-title":"A novel temporal expression pattern of three C\/EBP family members in differentiating myelomonocytic cells","volume":"80","author":"Scott","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102611_bib18","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1038\/sj.onc.1205324","article-title":"Transcriptional regulation of granulocyte and monocyte development","volume":"21","author":"Friedman","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.omtn.2025.102611_bib19","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1189\/jlb.1202622","article-title":"Cross-talk between regulators of myeloid development: C\/EBPalpha binds and activates the promoter of the PU.1 gene","volume":"74","author":"Kummalue","year":"2003","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.omtn.2025.102611_bib20","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1182\/blood-2007-03-080291","article-title":"C\/EBPalpha binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment","volume":"110","author":"Yeamans","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102611_bib21","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood.2018886077","article-title":"Identification of a novel enhancer of CEBPE essential for granulocytic differentiation","volume":"133","author":"Shyamsunder","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102611_bib22","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1038\/s41467-022-31332-1","article-title":"Transcription factor-driven coordination of cell cycle exit and lineage-specification in vivo during granulocytic differentiation : In memoriam Professor Niels Borregaard","volume":"13","author":"Theilgaard-M\u00f6nch","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102611_bib23","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1084\/jem.188.6.1173","article-title":"Upregulation of interleukin 6 and granulocyte colony-stimulating factor receptors by transcription factor CCAAT enhancer binding protein alpha (C\/EBP alpha) is critical for granulopoiesis","volume":"188","author":"Zhang","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omtn.2025.102611_bib24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2443.2008.01173.x","article-title":"Essential role of C\/EBP\u03b1 in G-CSF-induced transcriptional activation and chromatin modification of myeloid-specific genes","volume":"13","author":"Iida","year":"2008","journal-title":"Genes Cells"},{"key":"10.1016\/j.omtn.2025.102611_bib25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2010-02-270181","article-title":"Two types of C\/EBP\u03b1 mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models","volume":"117","author":"Kato","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102611_bib26","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1128\/MCB.15.10.5830","article-title":"PU.1 (Spi-1) and C\/EBP alpha regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene","volume":"15","author":"Hohaus","year":"1995","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102611_bib27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1084\/jem.20050067","article-title":"Loss of C\/EBP alpha cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocyte lineage","volume":"202","author":"Porse","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omtn.2025.102611_bib28","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/1078-0432.CCR-15-1054","article-title":"Inactivation of the p53\u2013KLF4\u2013CEBPA Axis in Acute Myeloid Leukemia","volume":"22","author":"Seipel","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2025.102611_bib29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s12185-010-0573-1","article-title":"Molecular mechanisms underlying deregulation of C\/EBP\u03b1 in acute myeloid leukemia","volume":"91","author":"Reckzeh","year":"2010","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.omtn.2025.102611_bib30","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.immuni.2004.11.006","article-title":"Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C\/EBP alpha","volume":"21","author":"Zhang","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2025.102611_bib31","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.leukres.2014.04.013","article-title":"Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT\/enhancer binding proteins in AML patients","volume":"38","author":"Musialik","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.omtn.2025.102611_bib32","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/86515","article-title":"AML1\u2013ETO downregulates the granulocytic differentiation factor C\/EBP\u03b1 in t(8;21) myeloid leukemia","volume":"7","author":"Pabst","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102611_bib33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/blood.2020009680","article-title":"CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome","volume":"139","author":"Taube","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102611_bib34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.omtn.2025.102611_bib35","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1128\/MCB.24.2.675-686.2004","article-title":"Phosphorylation of C\/EBPalpha inhibits granulopoiesis","volume":"24","author":"Ross","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102611_bib36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1084\/jem.20052242","article-title":"Block of C\/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations","volume":"203","author":"Radomska","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omtn.2025.102611_bib37","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1182\/blood-2022-166612","article-title":"FLT3-ITD Degrades CEBPA Via the Ubiquitin-Proteosome Pathway","volume":"140","author":"Gu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102611_bib38","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc.2017.36","article-title":"Drugging the 'undruggable' cancer targets","volume":"17","author":"Dang","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omtn.2025.102611_bib39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-020-00315-3","article-title":"Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials","volume":"5","author":"Lu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2025.102611_bib40","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","article-title":"Targeting transcription factors in cancer \u2014 from undruggable to reality","volume":"19","author":"Bushweller","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omtn.2025.102611_bib41","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41573-021-00199-0","article-title":"Advances in targeting \u2018undruggable\u2019 transcription factors with small molecules","volume":"20","author":"Henley","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102611_bib42","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omtn.2025.102611_bib43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.chembiol.2023.09.005","article-title":"Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges","volume":"31","author":"Hofman","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.omtn.2025.102611_bib44","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1089\/nat.2023.0068","article-title":"Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation","volume":"34","author":"Belgrad","year":"2024","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2025.102611_bib45","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102611_bib46","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41573-023-00704-7","article-title":"Amplifying gene expression with RNA-targeted therapeutics","volume":"22","author":"Khorkova","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102611_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25081902","article-title":"Tuning up Transcription Factors for Therapy","volume":"25","author":"Becskei","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2025.102611_bib48","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41467-023-36452-w","article-title":"A versatile, high-efficiency platform for CRISPR-based gene activation","volume":"14","author":"Heidersbach","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102611_bib49","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nchembio860","article-title":"Activating gene expression in mammalian cells with promoter-targeted duplex RNAs","volume":"3","author":"Janowski","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.omtn.2025.102611_bib50","doi-asserted-by":"crossref","first-page":"17337","DOI":"10.1073\/pnas.0607015103","article-title":"Small dsRNAs induce transcriptional activation in human cells","volume":"103","author":"Li","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102611_bib51","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/cr.2016.22","article-title":"saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription","volume":"26","author":"Portnoy","year":"2016","journal-title":"Cell Res."},{"key":"10.1016\/j.omtn.2025.102611_bib52","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.ymthe.2017.07.018","article-title":"Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer","volume":"25","author":"Voutila","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102611_bib53","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1038\/s41388-018-0126-2","article-title":"Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer","volume":"37","author":"Reebye","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.omtn.2025.102611_bib54","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-20-0414","article-title":"MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C\/EBP-\u03b1, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial","volume":"26","author":"Sarker","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2025.102611_bib55","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ymthe.2019.02.018","article-title":"Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice","volume":"27","author":"Zhou","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102611_bib56","article-title":"TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors","volume":"6","author":"Plummer","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omtn.2025.102611_bib57","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.omtn.2023.04.026","article-title":"PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration","volume":"32","author":"Su","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102611_bib58","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41419-024-07006-9","article-title":"Small RNA activation of CDH13 expression overcome BCR-ABL1-independent imatinib-resistance and their signaling pathway studies in chronic myeloid leukemia","volume":"15","author":"Su","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omtn.2025.102611_bib59","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102611_bib60","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1021\/acscentsci.9b00174","article-title":"Uptake and Fate of Fluorescently Labeled DNA Nanostructures in Cellular Environments: A Cautionary Tale","volume":"5","author":"Lacroix","year":"2019","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.omtn.2025.102611_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14112357","article-title":"Stability Study of mRNA-Lipid Nanoparticles Exposed to Various Conditions Based on the Evaluation between Physicochemical Properties and Their Relation with Protein Expression Ability","volume":"14","author":"Kamiya","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2025.102611_bib62","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202110137","article-title":"Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale","volume":"221","author":"Paramasivam","year":"2022","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102611_bib63","series-title":"Keystone Symposia\u2019s Delivery of Nucleic Acid Therapeutics Conference","author":"Hodgson","year":"2024"},{"key":"10.1016\/j.omtn.2025.102611_bib64","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1042\/bj20031253","article-title":"Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis","volume":"377","author":"Rejman","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.omtn.2025.102611_bib65","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1039\/D0CS01127D","article-title":"Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine","volume":"50","author":"Sousa de Almeida","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.omtn.2025.102611_bib66","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fgene.2012.00120","article-title":"miR-34 - a microRNA replacement therapy is headed to the clinic","volume":"3","author":"Bader","year":"2012","journal-title":"Front. Genet."},{"key":"10.1016\/j.omtn.2025.102611_bib67","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2174\/1389557515666150324123208","article-title":"MicroRNA Therapeutics: the Next Magic Bullet?","volume":"15","author":"Simonson","year":"2015","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.omtn.2025.102611_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/membranes10080177","article-title":"Macropinocytosis in Different Cell Types: Similarities and Differences","volume":"10","author":"Lin","year":"2020","journal-title":"Membranes"},{"key":"10.1016\/j.omtn.2025.102611_bib69","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1242\/jcs.053207","article-title":"Sequential signaling in plasma-membrane domains during macropinosome formation in macrophages","volume":"122","author":"Yoshida","year":"2009","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.omtn.2025.102611_bib70","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2011.06.025","article-title":"Role of the Clathrin Terminal Domain in Regulating Coated Pit Dynamics Revealed by Small Molecule Inhibition","volume":"146","author":"von Kleist","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102611_bib71","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0223-5234(03)00100-4","article-title":"An overview of inhibitors of Na(+)\/H(+) exchanger","volume":"38","author":"Masereel","year":"2003","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.omtn.2025.102611_bib72","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1111\/bph.14429","article-title":"Identification of novel macropinocytosis inhibitors using a rational screen of Food and Drug Administration-approved drugs","volume":"175","author":"Lin","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102611_bib73","unstructured":"Kwok, A. R., Nina; R., Vikash; Habib, R.; Catley, M.; Blakey, D.; Rossi, J.; Habib, N.. in 15th Annual Meeting of the Oligonucleotide Therapeutics Society (Munich, Germany, 2019)."},{"key":"10.1016\/j.omtn.2025.102611_bib74","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1038\/s41375-024-02430-4","article-title":"Rapid increase of C\/EBP\u03b1 p42 induces growth arrest of acute myeloid leukemia (AML) cells by Cop1 deletion in Trib1-expressing AML","volume":"38","author":"Sunami","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.omtn.2025.102611_bib75","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1532\/IJH97.05051","article-title":"Role of transcription factors C\/EBPalpha and PU.1 in normal hematopoiesis and leukemia","volume":"81","author":"Koschmieder","year":"2005","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.omtn.2025.102611_bib76","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1016\/j.celrep.2018.05.012","article-title":"Enhancer and Transcription Factor Dynamics during Myeloid Differentiation Reveal an Early Differentiation Block in Cebpa null Progenitors","volume":"23","author":"Pundhir","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2025.102611_bib77","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2004-07-2942","article-title":"AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations","volume":"106","author":"Choudhary","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102611_bib78","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1182\/blood-2002-06-1677","article-title":"Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations","volume":"101","author":"Mizuki","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102611_bib79","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1182\/blood-2012-01-402545","article-title":"Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3\/ITD AML","volume":"120","author":"Sexauer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102611_bib80","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102611_bib81","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41375-018-0032-1","article-title":"Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells","volume":"32","author":"Casado","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.omtn.2025.102611_bib82","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/blood-2015-05-646786","article-title":"All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3\/ITD+ leukemia stem cells in vitro and in vivo","volume":"127","author":"Ma","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102611_bib83","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1128\/MCB.21.11.3789-3806.2001","article-title":"c-Myc is a critical target for c\/EBPalpha in granulopoiesis","volume":"21","author":"Johansen","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102611_bib84","doi-asserted-by":"crossref","first-page":"22f.25.21","DOI":"10.1002\/0471142735.im22f05s104","article-title":"Differentiation and characterization of myeloid cells","volume":"104","author":"Gupta","year":"2014","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.omtn.2025.102611_bib85","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood.V73.1.131.131","article-title":"Differential Expression of CDllb\/CD18 (Mol) and Myeloperoxidase Genes During Myeloid Differentiation","volume":"73","author":"Rosmarin","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102611_bib86","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s13046-022-02542-8","article-title":"EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax","volume":"41","author":"Fooks","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2025.102611_bib87","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omtn.2025.102611_bib88","article-title":"Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling","volume":"5","author":"Chen","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omtn.2025.102611_bib89","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1158\/2767-9764.CRC-23-0379","article-title":"Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3\u03b2 Activation and c-Myc and Mcl-1 Proteasomal Degradation","volume":"4","author":"Lee","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.omtn.2025.102611_bib90","first-page":"1022","article-title":"A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia","volume":"106","author":"Lee","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.omtn.2025.102611_bib91","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2025.102611_bib92","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41408-021-00502-7","article-title":"The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML","volume":"11","author":"Qiao","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omtn.2025.102611_bib93","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/bloodadvances.2018029496","article-title":"Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia","volume":"3","author":"McMahon","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.omtn.2025.102611_bib94","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2003-06-1978","article-title":"Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C\/EBP\u03b1 expression","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102611_bib95","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1038\/onc.2017.151","article-title":"A tumor suppressor role for C\/EBP\u03b1 in solid tumors: more than fat and blood","volume":"36","author":"Louren\u00e7o","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.omtn.2025.102611_bib96","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/leu.2013.23","article-title":"C\/EBP\u03b1 and MYB regulate FLT3 expression in AML","volume":"27","author":"Volpe","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.omtn.2025.102611_bib97","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.actbio.2024.08.053","article-title":"Lipopolymer\/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemia","volume":"188","author":"Ansari","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.omtn.2025.102611_bib98","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102611_bib99","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3\u2013Internal Tandem Duplication Mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omtn.2025.102611_bib100","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102611_bib101","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1158\/0008-5472.CAN-15-2949","article-title":"Eradication of Acute Myeloid Leukemia with FLT3 Ligand\u2013Targeted miR-150 Nanoparticles","volume":"76","author":"Jiang","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2025.102611_bib102","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00277-019-03713-y","article-title":"Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo","volume":"98","author":"Jyotsana","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.omtn.2025.102611_bib103","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1182\/blood-2022-168154","article-title":"Synthetic Lipid Nanoparticles Actively Target Acute Myeloid Leukemia (AML) Cells and Induce Ferroptosis through Decreased Expression of Glutathione Peroxidase 4","volume":"140","author":"Lin","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102611_bib104","doi-asserted-by":"crossref","first-page":"LB192","DOI":"10.1158\/1538-7445.AM2023-LB192","article-title":"Abstract LB192: MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockade","volume":"83","author":"Plummer","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2025.102611_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100991","article-title":"Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment","volume":"57","author":"Serroukh","year":"2023","journal-title":"Blood Rev."},{"key":"10.1016\/j.omtn.2025.102611_bib106","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102611_bib107","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: how AML and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.omtn.2025.102611_bib108","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-21-0502","article-title":"Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy","volume":"13","author":"Linde","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omtn.2025.102611_bib109","doi-asserted-by":"crossref","DOI":"10.1126\/science.adn9083","article-title":"In vivo dendritic cell reprogramming for cancer immunotherapy","volume":"386","author":"Ascic","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102611_bib110","article-title":"Femoral bone marrow aspiration in live mice","volume":"89","author":"Chung","year":"2014","journal-title":"J. Vis. Exp."}],"updated-by":[{"DOI":"10.1016\/j.omtn.2025.102643","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000}}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125001659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125001659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:31:08Z","timestamp":1777321868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125001659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2162253125001659"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102611","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA activation of CEBPA improves leukemia treatment","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102611","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102611"}}